Abstract
The recent emergence of obesity as a major health threat in the industrialized world has intensified the search for novel and effective pharmacologic treatment. The proopiomelanocortin (POMC)-melanocortin 4 receptor (MC4R) axis has been shown to regulate food intake and energy homeostasis and is considered among the most promising antiobesity targets. Our initial efforts in this area have focused on affinity and selectivity directed optimization of the native β-MSH(5-22) sequence and resulted in the discovery of a potent MC4R agonist: Ac-Tyr-Arg-[Cys-Glu-His-D-Phe-Arg-Trp-Cys]-NH2 (10). Subcutaneous administration of this peptide produced an excellent in vivo efficacy in reducing food intake and increasing fat metabolism. Additionally, suppression of food intake was observed in wild type but not in MC4R deficient mice, suggesting that the effects observed in the wild type mice were mediated through MC4R signaling. Subsequent optimization efforts led to the identification of a novel series of disulfide constrained hexapeptides as exemplified by Ac-[hCys-His-D-Phe-Arg-Trp-Cys]-NH2 (100). These cyclic hexapeptides showed a further improved potency in binding MC4R and an enhanced selectivity over MC1R. At a dose of 0.07 mg/kg analog 102 reduced food intake by 38% and increased fat utilization by 58% in rats. These cyclic peptides provide novel and enhanced reagents for the elucidation of melanocortin receptors biology and may find applications in the treatment of obesity and related metabolic disorders.
Keywords: structure-activity relationship, agonist, peptide, obesity, MC4R, β-MSH, Melanocortin
Current Topics in Medicinal Chemistry
Title: Structure-Activity Relationships of β -MSH Derived Melanocortin-4 Receptor Peptide Agonists
Volume: 7 Issue: 11
Author(s): Liang Zeng Yan, Hansen M. Hsiung, Mark L. Heiman, Robert A. Gadski, Paul J. Emmerson, JeAnne Hertel, David Flora, Patrick Edwards, Dave Smiley, Lianshan Zhang, Saba Husain, Steven D.Kahl, Richard D.DiMarchi and John P.Mayer
Affiliation:
Keywords: structure-activity relationship, agonist, peptide, obesity, MC4R, β-MSH, Melanocortin
Abstract: The recent emergence of obesity as a major health threat in the industrialized world has intensified the search for novel and effective pharmacologic treatment. The proopiomelanocortin (POMC)-melanocortin 4 receptor (MC4R) axis has been shown to regulate food intake and energy homeostasis and is considered among the most promising antiobesity targets. Our initial efforts in this area have focused on affinity and selectivity directed optimization of the native β-MSH(5-22) sequence and resulted in the discovery of a potent MC4R agonist: Ac-Tyr-Arg-[Cys-Glu-His-D-Phe-Arg-Trp-Cys]-NH2 (10). Subcutaneous administration of this peptide produced an excellent in vivo efficacy in reducing food intake and increasing fat metabolism. Additionally, suppression of food intake was observed in wild type but not in MC4R deficient mice, suggesting that the effects observed in the wild type mice were mediated through MC4R signaling. Subsequent optimization efforts led to the identification of a novel series of disulfide constrained hexapeptides as exemplified by Ac-[hCys-His-D-Phe-Arg-Trp-Cys]-NH2 (100). These cyclic hexapeptides showed a further improved potency in binding MC4R and an enhanced selectivity over MC1R. At a dose of 0.07 mg/kg analog 102 reduced food intake by 38% and increased fat utilization by 58% in rats. These cyclic peptides provide novel and enhanced reagents for the elucidation of melanocortin receptors biology and may find applications in the treatment of obesity and related metabolic disorders.
Export Options
About this article
Cite this article as:
Liang Zeng Yan , Hansen M. Hsiung , Mark L. Heiman , Robert A. Gadski , Paul J. Emmerson , JeAnne Hertel , David Flora , Patrick Edwards , Dave Smiley , Lianshan Zhang , Saba Husain , Steven D.Kahl , Richard D.DiMarchi and John P.Mayer , Structure-Activity Relationships of β -MSH Derived Melanocortin-4 Receptor Peptide Agonists, Current Topics in Medicinal Chemistry 2007; 7 (11) . https://dx.doi.org/10.2174/156802607780906591
DOI https://dx.doi.org/10.2174/156802607780906591 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiovascular and Metabolic Effects of Ghrelin
Current Diabetes Reviews Relationships between Serotoninergic System and Skin Fibrotic
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Genetic Risk Factors for Depression in Alzheimer´s Disease Patients
Current Alzheimer Research G Protein-Activated Inwardly Rectifying Potassium Channels as Potential Therapeutic Targets
Current Pharmaceutical Design Anorexia of Aging
Current Nutrition & Food Science Classical Neurotransmitters and Neuropeptides Involved in Parkinson's Disease: Focus on Anti-Parkinsonian Drugs
Current Drug Therapy A New Protocol of Type 2 Diabetes Induction and Hydrocortisone Effects on Beta-Cells Signaling in Mice
Current Chemical Biology Childhood Alopecia Areata: An Overview of Treatment and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Long-Acting Beta-Agonists and their Association with Inhaled Corticosteroids in COPD
Current Medicinal Chemistry Double-Edged Sword of Novel Anti-Cancer Treatment: Proteasome Inhibition in the Growth Plate Causes Impairment of Longitudinal Bone Growth
Current Pediatric Reviews Pathophysiology of Sepsis in the Elderly: Clinical Impact and Therapeutic Considerations
Current Drug Targets Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review
Current Neuropharmacology Calcium-engaged Mechanisms of Nongenomic Action of Neurosteroids
Current Neuropharmacology Influence of a Novel Inhibitor (UM8190) of Prolylcarboxypeptidase (PRCP) on Appetite and Thrombosis
Current Medicinal Chemistry Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 1: Overview of the Chemical and Biological Research
Current Drug Targets The Vitamin D Neuroendocrine System as a Target for Novel Neurotropic Drugs
CNS & Neurological Disorders - Drug Targets Abnormalities in Kynurenine Pathway Metabolism in Treatment-Resistant Depression and Suicidality: A Systematic Review
CNS & Neurological Disorders - Drug Targets Ghrelin: A Molecular Target for Weight Regulation, Glucose and Lipid Metabolism
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Long-Chain Omega-3 Fatty Acid Deficiency in Mood Disorders: Rationale for Treatment and Prevention
Current Drug Discovery Technologies Selective Serotonin Re-Uptake Inhibitors for the Treatment of Depression in Coronary Artery Disease and Chronic Heart Failure: Evidence for Pleiotropic Effects
Cardiovascular & Hematological Agents in Medicinal Chemistry